Toxicité pulmonaire aiguë de la gemcitabine: Un rôle pour l'exposition à l'amiante?

Translated title of the contribution: Acute pulmonary toxicity due to gemcitabine: A role for asbestos exposure?

F. Barlési, C. Doddoli, C. Gimenez, L. Greillier, G. Lima, J. P. Kleisbauer

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Introduction: Gemcitabine is an important drug in the treatment of non-small cell lung cancer. Myelosuppression is the most common toxic effect but its use sometimes leads to severe pulmonary toxicity by means of diffuse alveolar damage or subacute interstitial pneumonitis. Methods: A retrospective study was made of all the patients treated in our department with this drug, alone or in combination. Episodes of acute dyspnoea during the course of chemotherapy were identified, and data were collected concerning the past history, the illness and the treatment in patients who had developed a respiratory failure attributable to gemcitabine. Results: 312 patients had been treated with gemcitabine over a 5 year period and 18 had developed episodes of acute dyspnoea, of which 6 (1.9%) were attributed to the drug itself. Of these patients 4 had notifiable industrial disease (no. 30bis) secondary to asbestos exposure (odds rado = 85, 95% confidence interval 13-546) and 5 were active smokers. The possible role of intracellular ATP pool depletion secondary to asbestos exposure or smoking as a predisposing factor in the development of gemcitabine pulmonary toxicity is discussed. Conclusion: Smoking and asbestos exposure should be taken into account in future studies of gemcitabine pulmonary toxicity.

Translated title of the contributionAcute pulmonary toxicity due to gemcitabine: A role for asbestos exposure?
Original languageFrench
Pages (from-to)201-206
Number of pages6
JournalRevue des Maladies Respiratoires
Volume20
Issue number2 I
Publication statusPublished - 1 Apr 2003
Externally publishedYes

Cite this